AU670962B2 - Method for antagonizing inositol 1,4,5-triphosphate - Google Patents

Method for antagonizing inositol 1,4,5-triphosphate Download PDF

Info

Publication number
AU670962B2
AU670962B2 AU48417/93A AU4841793A AU670962B2 AU 670962 B2 AU670962 B2 AU 670962B2 AU 48417/93 A AU48417/93 A AU 48417/93A AU 4841793 A AU4841793 A AU 4841793A AU 670962 B2 AU670962 B2 AU 670962B2
Authority
AU
Australia
Prior art keywords
document
international
date
search
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48417/93A
Other languages
English (en)
Other versions
AU4841793A (en
Inventor
Kenneth A Stauderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU4841793A publication Critical patent/AU4841793A/en
Application granted granted Critical
Publication of AU670962B2 publication Critical patent/AU670962B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU48417/93A 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate Ceased AU670962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95239392A 1992-09-28 1992-09-28
US952393 1992-09-28
PCT/US1993/008168 WO1994007507A1 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Publications (2)

Publication Number Publication Date
AU4841793A AU4841793A (en) 1994-04-26
AU670962B2 true AU670962B2 (en) 1996-08-08

Family

ID=25492868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48417/93A Ceased AU670962B2 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Country Status (13)

Country Link
EP (1) EP0661982A1 (enrdf_load_html_response)
JP (1) JPH08502068A (enrdf_load_html_response)
KR (1) KR950703347A (enrdf_load_html_response)
AU (1) AU670962B2 (enrdf_load_html_response)
CA (1) CA2145681A1 (enrdf_load_html_response)
HU (1) HUT70192A (enrdf_load_html_response)
IL (1) IL107066A (enrdf_load_html_response)
MX (1) MX9305933A (enrdf_load_html_response)
NO (1) NO951163L (enrdf_load_html_response)
NZ (1) NZ256178A (enrdf_load_html_response)
TW (1) TW260663B (enrdf_load_html_response)
WO (1) WO1994007507A1 (enrdf_load_html_response)
ZA (1) ZA936978B (enrdf_load_html_response)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2978995A (en) * 1994-06-30 1996-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for treating cell proliferative disorders by modulating signal transduction
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
AU3409197A (en) * 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0915651A4 (en) 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
AU2002214886A1 (en) * 2000-11-09 2002-05-21 Contrimmune Biotechnology Inc Therapeutic uses for IP3 receptor-mediated calcium channel modulators
JP2014531425A (ja) 2011-09-02 2014-11-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781479A (en) * 1953-08-27 1957-08-21 Ciba Ltd New polyureas and process for making them
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers

Also Published As

Publication number Publication date
KR950703347A (ko) 1995-09-20
MX9305933A (es) 1994-04-29
HUT70192A (en) 1995-09-28
TW260663B (enrdf_load_html_response) 1995-10-21
CA2145681A1 (en) 1994-04-14
ZA936978B (en) 1994-04-18
NZ256178A (en) 1997-03-24
JPH08502068A (ja) 1996-03-05
HU9500891D0 (en) 1995-05-29
AU4841793A (en) 1994-04-26
WO1994007507A1 (en) 1994-04-14
IL107066A0 (en) 1993-12-28
IL107066A (en) 1998-01-04
EP0661982A1 (en) 1995-07-12
NO951163D0 (no) 1995-03-27
NO951163L (no) 1995-03-27

Similar Documents

Publication Publication Date Title
AU670962B2 (en) Method for antagonizing inositol 1,4,5-triphosphate
Leysen et al. Serotonergic component of neuroleptic receptors
Laduron et al. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
Browning et al. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors
DE69908414T2 (de) Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
Mendelsohn et al. Phencyclidine receptors in rat brain cortex
Hanson et al. UK‐78,282, a novel piperidine compound that potently blocks the Kv1. 3 voltage‐gated potassium channel and inhibits human T cell activation
CA2078572A1 (en) Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
Nagasawa et al. . beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo
Aricioglu et al. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system
Kostowski et al. The abilities of 5-HT3 receptor antagonist ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats
Church et al. Interactions of dextromethorphan with theN-methyl-d-aspartate receptor-channel complex: single channel recordings
Moore et al. Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor
Sanders-Bush et al. 5HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug
Rowan et al. Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine
Syvälahti et al. Decrease in the number of rat brain dopamine and muscarinic receptors after chronic alcohol intake
Purcell et al. Characterisation of a functional polyamine site on rat mast cells: association with a NMDA receptor macrocomplex
Thayer et al. The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors.
Greenberg et al. Phenytoin interacts with calcium channels in brain membrances
Harris et al. Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain
Baumgold et al. Pharmacological differences between muscarinic receptors coupled to phosphoinositide turnover and those coupled to adenylate cyclase inhibition
IJzerman et al. Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine
Mei et al. Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells.
Araujo et al. Characterization of [3H] AF‐DX 116 binding sites in the rat brain: Evidence for heterogeneity of muscarinic‐M2 receptor sites
Lee et al. Potent enhancement of [3H] nitrendipine binding in rat cerebral cortical and cardiac homogenates: a putative mechanism for the action of MDL 12,330 A.